SCHEMBL1566200

SCHEMBL1566200

CCCCC(Oc1ccc2ccccc2c1)C(=O)Nc1nccs1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.58
▸ RAB9A P51151 4/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ ALDH1A1 P00352 1/20 0.58
▸ MAPT P10636 1/20 0.58
▸ NFKB1 P19838 1/20 0.58
▸ NFKB2 Q00653 1/20 0.58
▸ RELA Q04206 1/20 0.58
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ HSPA5 P11021 2/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ KCNA5 P22460 1/20 0.48
▸ SIRT2 Q8IXJ6 1/20 0.48
▸ PPARG P37231 2/20 0.48
▸ PPARA Q07869 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1566465 0.88 CYP1A2 (0.55) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL1564841 0.88 CYP1A2 (0.55) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL1565317 0.86 LMNA (0.56) NPC1RAB9AMEN1KMT2ACYP1A2
SCHEMBL1565298 0.86 NPC1 (0.56) NPC1RAB9AMEN1KMT2ACYP1A2
SCHEMBL1565403 0.85 LMNA (0.50) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL1565765 0.85 LMNA (0.53) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL1565655 0.85 HSPA5 (0.52) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL1564907 0.85 TP53 (0.55) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL1565038 0.84 RAB9A (0.54) NPC1RAB9AMAPTCYP1A2CYP3A4
SCHEMBL2654200 0.84 NPC1 (0.43) NPC1RAB9AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171411-A1 Amide derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2003-09-11 — — US claimed
EP-1336607-A1 Amide derivatives as glucokinase activators NOVO NORDISK A/S (DK) 2003-08-20 — — EP claimed
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 — — EP disclosed
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 — — EP disclosed
EP-1458382-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2004-09-22 — — EP disclosed
US-20030171411-A1 Amide derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2003-09-11 — — US disclosed
EP-1336607-A1 Amide derivatives as glucokinase activators NOVO NORDISK A/S (DK) 2003-08-20 — — EP disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 — — WO disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171411-A1 Amide derivatives as therapeutic agents GK, GCKR, GCK NPC1 271/4885RAB9A 3291/4885MEN1 3187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback